Quick Answer
Spero Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $40.27 million for the year ending 2025.
- Spero Therapeutics, Inc. showed a decrease of -23.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Spero Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 15,628.5%.
- Historical annual values: Fiscal year 2025: $40.27 million | Fiscal year 2024: $52.89 million | Fiscal year 2023: $76.33 million | Fiscal year 2022: $109.11 million | Fiscal year 2021: $112.58 million | Fiscal year 2020: $85.21 million | Fiscal year 2019: $29.73 million | Fiscal year 2018: $34.08 million | Fiscal year 2017: $87.29 million | Fiscal year 2016: $10.32 million | Fiscal year 2015: $5.69 million | Fiscal year 2014: $256.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: